Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03138889
Title	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Acronym	PROPEL
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Nektar Therapeutics
Indications	Advanced Solid Tumor lung non-small cell carcinoma
Therapies	NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP \| DEU \| AUS